Pierre Fumoleau

List of Publications by Year in descending order

32 papers	4,379 citations	361413 20 h-index	414414 32 g-index
33 all docs	33 docs citations	33 times ranked	4803 citing authors

#	Article	IF	Citations
1	Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. Journal of Clinical Oncology, 2002, 20, 2812-2823.	1.6	1,034
2	Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. Journal of Clinical Oncology, 2006, 24, 5664-5671.	1.6	512
3	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 741-748.	10.7	314
4	Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells. Clinical Cancer Research, 2008, 14, 2413-2420.	7.0	277
5	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer. Journal of Clinical Oncology, 2007, 25, 3399-3406.	1.6	273
6	Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 759-769.	6.3	271
7	Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. Journal of Clinical Oncology, 2011, 29, 149-156.	1.6	222
8	In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. Journal of Pathology, 2011, 224, 389-400.	4.5	204
9	Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial. Journal of Clinical Oncology, 2005, 23, 2686-2693.	1.6	179
10	Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. Journal of the National Cancer Institute, 2016, 108, djv330.	6.3	159
11	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncology, The, 2011, 12, 527-539.	10.7	116
12	Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2011, 125, 65-72.	2.5	115
13	A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nature Communications, 2016, 7, 12222.	12.8	113
14	Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1753-1760.	1.6	102
15	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet, The, 2019, 393, 2591-2598.	13.7	102
16	Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial. Journal of Clinical Oncology, 2003, 21, 298-305.	1.6	93
17	Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. European Journal of Cancer, 2015, 51, 1660-1666.	2.8	63
18	Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. Seminars in Oncology, 2004, 31, 45-50.	2.2	61

#	Article	IF	Citations
19	Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: A pooled analysis of two randomised trials. European Journal of Cancer, 2014, 50, 506-516.	2.8	41
20	Epirubicin-Docetaxel Combination in First-Line Chemotherapy for Patients With Metastatic Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 328-335.	1.3	33
21	The 21-gene Recurrence ScoreÂ® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). BMC Cancer, 2018, 18, 526.	2.6	24
22	Challenges in the implementation of trastuzumab biosimilars. Anti-Cancer Drugs, 2015, 26, 1009-1016.	1.4	12
23	GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients. Oncotarget, 2016, 7, 77358-77364.	1.8	11
24	Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients: Which is the Reference Today?. Journal of Clinical Oncology, 2003, 21, 1190-1191.	1.6	10
25	Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab. Breast, 2018, 41, 1-7.	2.2	10
26	Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes. Breast Cancer Research, 2017, 19, 98.	5.0	9
27	Feasibility and Safety of Weekly Sequential Epirubicin-Paclitaxel as Adjuvant Treatment for Operable Breast Cancer Patients Older than 70 Years. Clinical Breast Cancer, 2011, 11, 235-240.	2.4	4
28	Prognostic factors of young women (â‰¤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up. Bulletin Du Cancer, 2013, 100, E22-E29.	1.6	4
29	Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab inÂHER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. European Journal of Cancer, 2017, 81, 151-160.	2.8	4
30	Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up. Bulletin Du Cancer, 2012, 99, E64-E74.	1.6	3
31	Treatment beyond taxanes, emerging new cytotoxic agents. European Journal of Cancer, Supplement, 2009, 7, 8-13.	2.2	2
32	Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. Npj Breast Cancer, 2017, 3, 4.	5.2	2